BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15208820)

  • 1. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors.
    Haluska M; Anthony ML
    Clin J Oncol Nurs; 2004 Jun; 8(3):263-7. PubMed ID: 15208820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
    Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-brain barrier disruption in the treatment of brain tumors.
    Blanchette M; Fortin D
    Methods Mol Biol; 2011; 686():447-63. PubMed ID: 21082387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
    Neuwelt EA; Rapoport SI
    Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local convection-enhanced delivery of chemotherapeutic agent transiently opens blood-brain barrier and improves efficacy of systemic chemotherapy in intracranial xenograft tumor model.
    Nakamura T; Saito R; Sugiyama S; Sonoda Y; Kumabe T; Tominaga T
    Cancer Lett; 2011 Nov; 310(1):77-83. PubMed ID: 21763069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
    Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
    Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
    Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
    Dahlborg SA; Henner WD; Crossen JR; Tableman CM; Petrillo A; Braziel R; Neuwelt EA
    Cancer J Sci Am; 1996; 2(3):166-74. PubMed ID: 9166517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
    Fortin D; Gendron C; Boudrias M; Garant MP
    Cancer; 2007 Feb; 109(4):751-60. PubMed ID: 17211866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
    Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
    J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
    Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
    Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
    J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-brain barrier and treatment of central nervous system tumors.
    Wiranowska M
    J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
    Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
    Kemper EM; Boogerd W; Thuis I; Beijnen JH; van Tellingen O
    Cancer Treat Rev; 2004 Aug; 30(5):415-23. PubMed ID: 15245774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seizure-promoting effect of blood-brain barrier disruption.
    Marchi N; Angelov L; Masaryk T; Fazio V; Granata T; Hernandez N; Hallene K; Diglaw T; Franic L; Najm I; Janigro D
    Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
    Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.
    Doolittle ND; Miner ME; Hall WA; Siegal T; Jerome E; Osztie E; McAllister LD; Bubalo JS; Kraemer DF; Fortin D; Nixon R; Muldoon LL; Neuwelt EA
    Cancer; 2000 Feb; 88(3):637-47. PubMed ID: 10649259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.